An NBC affiliate in Knoxville covered the story of our ribbon-cutting ceremony today - watch for yourself below!
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.
Wednesday 18 September 2024
Monday 16 September 2024
BioLargo to Host Ribbon-Cutting Event for Battery Pilot Manufacturing Facility
Westminster, CA – September 16, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it will be hosting a ribbon-cutting ceremony to showcase its pilot-scale manufacturing facility for its CellinityTM next-generation battery energy storage technology. The invite-only event will take place on September 21, 2024, at BioLargo’s engineering headquarters and manufacturing facilities in Oak Ridge, Tennessee.
According to BioLargo President and CEO Dennis P. Calvert, “We
are excited to share more information about Cellinity at this event, including
showcasing the design of our larger Cellinity cell that will be used in
commercial Cellinity battery systems. While much work is left to be done before
the facility is producing finished, commercial-grade batteries, we’re excited
to celebrate the impressive progress our engineers have made toward that goal.”
He continued, “We are also thrilled to host our potential
international partners from Norway, where we hope to advance our business model
to ‘sell factories, not batteries’. Much like North America, Northern Europe
has made tremendous headway in developing renewable energy projects, but just
like in America, safe and affordable battery energy storage systems are crucial
to empowering the transition to green energy in Europe. We have a number of
projects in development.”
Learn more about Cellinity at www.BioLargoEnergy.com.
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences
innovator and engineering services solution provider. Our core products address
PFAS contamination, achieve advanced water and wastewater treatment, control
odor and VOCs, improve air quality, enable energy-efficiency and safe on-site
energy storage, and control infections and infectious disease. Our approach is
to invent or acquire novel technologies, develop them into product offerings,
and extend their commercial reach through licensing and channel partnerships to
maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include without limitation those about
BioLargo’s (the “Company”) expectations regarding anticipated revenue; and
plans for future operations. These statements involve risks and uncertainties,
and actual results may differ materially from any future results expressed or
implied by the forward-looking statements. Risks and uncertainties include without
limitation: the effect of regional economic conditions on the Company’s
business, including effects on purchasing decisions by consumers and
businesses; the ability of the Company to compete in markets that are highly
competitive and subject to rapid technological change; the ability of the
Company to manage frequent introductions and transitions of products and
services, including delivering to the marketplace, and stimulating customer
demand for, new products, services, and technological innovations on a timely
basis; the dependency of the Company on the performance of distributors of the
Company’s products. More information on these risks and other potential factors
that could affect the Company’s business and financial results is included in
the Company’s filings with the SEC, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
Monday 9 September 2024
Clyra Medical Technologies, a Subsidiary of BioLargo, Appoints Dr. Steven J. Kavros as Chief Medical Officer
Dr. Kavros brings a wealth of medical expertise and experience in advanced wound healing and limb preservation to his new role at Clyra. He spent over 20 years at the prestigious Mayo Clinic in Rochester, MN, where he served as Director at the Gonda Vascular Wound Healing Center, and was involved in both research and patient care. He was also deeply engaged in medical education as Associate Professor at the Mayo Clinic's Alix School of Medicine.
Dr. Kavros is also an accomplished researcher and speaker, having given over 1,800 presentations related to his research activities at national and international conferences, and lead author of numerous peer-reviewed papers centered on new medical technologies and evidence-based medicine.
In addition to his clinical and academic achievements, Dr. Kavros has a proven track record in the medical device industry, successfully bringing to market multiple products in advanced wound healing, limb preservation, and orthopedics. He has also served in leadership roles at EPIEN Medical, TEI Biosciences, Miromatrix Medical, and Innovacyn.
Dr. Kavros earned a bachelor's degree in Biology with honors and a minor in Chemistry from Rutgers University and subsequently graduated from Temple University School of Podiatric Medicine with highest honors in surgery, orthopedics, biomechanics and podiatric medicine. Dr. Kavros is also a certified wound specialist through the American Board of Wound Management, a fellow of the American College of Certified Wound Specialists, and a founding member of the American Professional Wound Care Association, where he also served as scientific chair and later as its president from 2015-2019.
Clyra CEO Steve Harrison commented "Dr. Kavros' unique blend of clinical expertise and business insight will prove invaluable to support our significant investments for at-scale manufacturing and distribution of our Bioclynse product. His skills in leadership, team building, and entrepreneurship align perfectly with Clyra's vision and goals."
About Clyra Medical Technologies, Inc.
Clyra Medical Technologies, founded on our mission of "Make Lives Better", is a healthcare company that develops and commercializes products designed to safely treat wound and skin infections and promote wound healing, while reducing the need for antibiotics.
Clyra Medical Technologies is a proud member of the BioLargo Family of Companies (www.biolargo.com). Clyra is a subsidiary of BioLargo, Inc., a publicly traded company, with the stock symbol (OTCQX:BLGO) BioLargo is a technology innovator and solutions provider focused on some of the world's most pressing human health and environmental challenges including advanced water treatment, environmental remediation, air quality control, medical technologies, and more.
About BioLargo, Inc.
BioLargo, Inc. (OTCQX: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
dennis.calvert@biolargo.com
888-400-2863
Subscribe to:
Posts (Atom)